Impact of the extent of recurrent laryngeal nerve lymphadenectomy on thoracic esophageal squamous cell carcinoma: a real-world multicentre study
European Journal of Cardio-Thoracic Surgery · 2023
DOI: 10.1093/ejcts/ezad168 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Cardio-Thoracic Surgery, 2023. Verfasst von Sukai Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, the Second Affiliated Hospital of Soochow University, Suzhou, China. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Jiangsu Key Research and Development Plan.
Abstract (Originalsprache)
OBJECTIVES To determine the impact of recurrent laryngeal nerve (RLN) lymph node (LN) dissection on survival and postoperative complications in patients with oesophageal squamous cell carcinoma (ESCC). METHODS Patients with cT1-4N0-3M0 thoracic ESCC who underwent oesophagectomy and two-field lymphadenectomy from three institutions were included. The entire cohort was divided into three groups that underwent the total two-field lymphadenectomy (T-2FL), standard two-field lymphadenectomy (S-2FL) or unilateral RLN-LN dissection plus S-2FL (U-2FL) based on the extent of RLN-LN dissection. Subgroup analyses were also performed and were stratified by treatment modality. RESULTS Both the U-2FL and T-2FL groups had significantly superior outcomes compared with the S-2FL group (overall survival: U-2FL versus S-2FL: P = 0.002; T-2FL versus S-2FL: P < 0.001; recurrence-free survival: U-2FL versus S-2FL: P = 0.01; T-2FL versus S-2FL: P < 0.001). Moreover, no significant differences were observed between U-2FL and T-2FL regarding overall survival (P > 0.05) and recurrence-free survival (P > 0.05), irrespective of administration of neoadjuvant therapy plus oesophagectomy or upfront oesophagectomy. Additionally, the extent of RLN-LN dissection was not an independent predictor of stage migration (P = 0.14) but was for postoperative nodal upstaging (P = 0.02). Notably, S-2FL brought significantly lowered risk in postoperative complications, especially for RLN palsy, when compared with T-2FL (P = 0.002) but not U-2FL (P = 0.72). CONCLUSIONS Adequacy of RLN-LN dissection is an important prognosticator for improved overall survival and recurrence-free survival in patients with thoracic ESCC. U-2FL may serve as an alternative to T-2FL in selected populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, the Second Affiliated Hospital of Soochow University, Suzhou, China.
- Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Thoracic Surgery, Section of Esophageal Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
ORCID-Profile: Yongbing Chen
Förderung
- Jiangsu Key Research and Development Plan
Zitieren
APA
Xu, S., Chen, D., Liu, Z., Song, P., Zheng, Y., Xue, X., Sang, Y., Li, Z., & Chen, Y. (2023). Impact of the extent of recurrent laryngeal nerve lymphadenectomy on thoracic esophageal squamous cell carcinoma: a real-world multicentre study. European Journal of Cardio-Thoracic Surgery. https://doi.org/10.1093/ejcts/ezad168
Vancouver
Xu S, Chen D, Liu Z, Song P, Zheng Y, Xue X, et al. Impact of the extent of recurrent laryngeal nerve lymphadenectomy on thoracic esophageal squamous cell carcinoma: a real-world multicentre study. European Journal of Cardio-Thoracic Surgery. 2023. doi:10.1093/ejcts/ezad168
BibTeX
@article{Xu2023,
author = {Xu, Sukai and Chen, Donglai and Liu, Zhichao and Song, Peidong and Zheng, Yujia and Xue, Xiang and Sang, Yonghua and Li, Zhigang and Chen, Yongbing},
title = {Impact of the extent of recurrent laryngeal nerve lymphadenectomy on thoracic esophageal squamous cell carcinoma: a real-world multicentre study},
journal = {European Journal of Cardio-Thoracic Surgery},
year = {2023},
doi = {10.1093/ejcts/ezad168}
}
EUVIMED